All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ibrutinib,Venetoclax
Therapeutic Area: Oncology Product Name: Imbruvica
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Janssen Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2020
Details:
The results show the ibrutinib plus venetoclax combination providing continued disease-free survival for CLL patients once treatment is complete.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Venetoclax,Ibrutinib
Therapeutic Area: Oncology Product Name: Venclexta
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
AbbVie will present updated results from the CAPTIVATE study, evaluating disease-free survival in previously untreated patients with chronic lymphocyctic leukemia/small lymphocytic leukemia who received ibrutinib (IMBRUVICA®) + venetoclax (VENCLEXTA®/ VENCLYXTO®) regimen.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CD30.CAR-T,Fludarabine Phosphate,Bendamustine Hydrochloride
Therapeutic Area: Oncology Product Name: TT11
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2021
Details:
The PRIME designation was granted to TT11 by EMA on the back of promising clinical data from two Phase I/II trials in R/R cHL conducted at Baylor College of Medicine and University of North Carolina Lineberger Comprehensive Cancer Center.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CD30 CAR-T
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2020
Details:
The designation is based on the data of two independent Phase I/II trials, which show promising efficacy and strong safety profile of the therapy in Hodgkin lymphoma patients.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
